Review article · 2026

GLP-1 Receptor Agonists

Clifford james Rosen, Julie R. Ingelfinger

New England Journal of Medicine, 394(13), 1313–1324 · Published 1 April 2026 · DOI 10.1056/nejmra2500106

View at the publisherCite this paper

In brief

“GLP-1 Receptor Agonists” is a 2026 review article by Clifford james Rosen and Julie R. Ingelfinger, published in New England Journal of Medicine. OpenAlex counts 130 citations as of 16 November 2026, which puts it in the top 1% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
130
Most cited in
2026 (130)
Field-weighted impact
98.41
References
73
Authors
2

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rosen, C. J., & Ingelfinger, J. R. (2026). GLP-1 Receptor Agonists. New England Journal of Medicine, 394(13), 1313–1324. https://doi.org/10.1056/nejmra2500106

MLA 9

Rosen, Clifford james, and Julie R. Ingelfinger. “GLP-1 Receptor Agonists.” New England Journal of Medicine, vol. 394, no. 13, 2026, pp. 1313–1324. https://doi.org/10.1056/nejmra2500106.

Chicago

Rosen, Clifford james and Julie R. Ingelfinger. 2026. “GLP-1 Receptor Agonists.” New England Journal of Medicine 394 (13): 1313–1324. https://doi.org/10.1056/nejmra2500106.

Harvard

Rosen, C. J. and Ingelfinger, J. R. (2026) ‘GLP-1 Receptor Agonists’, New England Journal of Medicine, 394(13), pp. 1313–1324. doi:10.1056/nejmra2500106.

IEEE

C. J. Rosen and J. R. Ingelfinger, “GLP-1 Receptor Agonists,” New England Journal of Medicine, vol. 394, no. 13, pp. 1313–1324, 2026, doi: 10.1056/nejmra2500106.

BibTeX

@article{rosen2026receptor,
  title     = {{GLP-1 Receptor Agonists}},
  author    = {Rosen, Clifford james and Ingelfinger, Julie R.},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  volume    = {394},
  number    = {13},
  pages     = {1313--1324},
  doi       = {10.1056/nejmra2500106},
  url       = {https://doi.org/10.1056/nejmra2500106}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management

  • GLP-1 receptor agonists
  • incretin analogues
  • type 2 diabetes
  • obesity
  • glucose-dependent insulinotropic polypeptide
  • insulin secretion
  • gastric emptying
  • glucagon secretion

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Rosen, C. J., & Ingelfinger, J. R. (2026). GLP-1 Receptor Agonists. New England Journal of Medicine, 394(13), 1313–1324. https://doi.org/10.1056/nejmra2500106

How many times has this paper been cited?

130 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Clifford james Rosen, Julie R. Ingelfinger.

What is the DOI of this paper?

10.1056/nejmra2500106, permanently at https://doi.org/10.1056/nejmra2500106. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.